Haleon Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on October 4, 2024, reports a material change in major shareholdings for Haleon Plc. The filing details a reduction in Pfizer Inc.'s voting interest in Haleon following a secondary offering and an off-market share sale completed on October 3, 2024.
Key Financial Metrics and Shareholding Data
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on equity ownership changes.
- Shareholder: Pfizer Inc.
- Previous Voting Interest: 22.58% (22.58% via shares, 0% via financial instruments).
- Current Voting Interest: 15.04% (15.04% via shares, 0% via financial instruments).
- Total Voting Rights Held: 1,361,709,764 shares.
- Breakdown of Holdings: 967,251,860 Ordinary Shares (10.68%) and 394,457,904 Restricted ADSs (4.36%).
- Total Issued Voting Capital: 9,053,360,882 ordinary shares.
Material Changes Versus Prior Period
Pfizer Inc. reduced its total voting stake in Haleon by approximately 7.54 percentage points. This reduction resulted from two specific transactions:
- Secondary Offering: Pfizer sold 640,000,000 Haleon ordinary shares pursuant to an offering announced on September 30, 2024.
- Off-Market Sale: Pfizer sold an additional 60,526,315 ordinary shares directly to Haleon under a previously approved share purchase deed.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook. It does not disclose new risks or contingencies beyond the standard notification of the change in major holdings. The transaction was executed through State Street Nominees Limited and Guaranty Nominees Limited, which hold legal title on Pfizer's behalf.
Key Facts for Investor Verification
- Verify the exact number of shares sold in the secondary offering versus the off-market transaction to confirm the total reduction in Pfizer's stake.
- Confirm the current total issued voting share capital of Haleon (stated as 9,053,360,882) to validate the percentage calculations.
- Review the terms of the share purchase deed between Haleon and Pfizer regarding the off-market sale of 60,526,315 shares.
- Monitor future filings to determine if Pfizer intends to further reduce its stake below the 15% threshold.